Tremfya received FDA approval on December 16, 2017 [1]. This approval was for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy [1].
When did Tremfya get approved for psoriatic arthritis?
The FDA approved Tremfya for adults with active psoriatic arthritis on December 20, 2019 [2].
What is Tremfya used to treat?
Tremfya (guselkumab) is approved for two main indications in adults:
* Moderate to severe plaque psoriasis in individuals who are candidates for systemic therapy or phototherapy [1].
* Active psoriatic arthritis [2].
How long does patent protection for Tremfya last?
Drug patent expiry dates are complex and can involve multiple patents. Information on specific patent timelines for Tremfya is available through resources that track drug patents. DrugPatentWatch.com provides detailed patent information, including expiry dates for various drug patents [3].
Who makes Tremfya?
Janssen Biotech, Inc., a Johnson & Johnson company, manufactures Tremfya [1, 2].
How does Tremfya work?
Tremfya is an interleukin-23 (IL-23) inhibitor. IL-23 is a naturally occurring cytokine that plays a key role in inflammatory processes [4]. By blocking IL-23, Tremfya helps to reduce inflammation associated with plaque psoriasis and psoriatic arthritis [4].
What are the alternatives to Tremfya for plaque psoriasis?
Several other biologic medications are approved for moderate to severe plaque psoriasis, including TNF inhibitors (e.g., Humira, Remicade), IL-17 inhibitors (e.g., Cosentyx, Taltz), and IL-12/23 inhibitors (e.g., Stelara) [5]. The choice of treatment often depends on individual patient factors, including disease severity, previous treatment responses, and co-existing conditions.
Can biosimilars be made for Tremfya?
The development of biosimilars for biologic drugs like Tremfya is possible after patent expiry, but the process is complex and regulated. Biosimilarity means the biosimilar is highly similar to the reference product with no clinically meaningful differences in safety, purity, and potency [6].
What is the difference between Tremfya and Stelara for psoriatic arthritis?
Both Tremfya and Stelara are biologic medications used to treat active psoriatic arthritis. Tremfya targets IL-23, while Stelara targets both IL-12 and IL-23 [4, 5]. Clinical studies have compared the efficacy and safety of these and other treatments, with outcomes varying among individuals [5].
What clinical trials led to Tremfya's approval?
The FDA approval of Tremfya was based on results from several pivotal clinical trials. For plaque psoriasis, key studies included VOYAGE 1, VOYAGE 2, and VOYAGE 3, which demonstrated Tremfya's efficacy and safety in treating moderate to severe plaque psoriasis [1, 4]. For psoriatic arthritis, studies such asSPIRIT-P1 and SPIRIT-P2 supported its approval for that indication [2, 4].
Sources:
1. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approval-packages-2017
2. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approval-packages-2019
3. https://drugpatentwatch.com/
4. https://www.tremfya.com/
5. https://www.psoriasis.org/treatment-options/biologics/
6. https://www.fda.gov/vaccines-blood-biologics/biosimilars/understanding-biosimilars